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Divergent expression patterns of 
pituitary gonadotropin subunit and 
GnRH receptor genes to continuous 
GnRH in vitro and in vivo
Marija M. Janjic1,2,4, Rafael M. prévide1,4, Patrick A. fletcher  3, Arthur Sherman  3, 
Kosara Smiljanic1, Daniel Abebe1, Ivana Bjelobaba1,2 & Stanko S. Stojilkovic1*
Continuous, as opposed to pulsatile, delivery of hypothalamic gonadotropin-releasing hormone 
(GnRH) leads to a marked decrease in secretion of pituitary gonadotropins LH and FSH and impairment 
of reproductive function. Here we studied the expression profile of gonadotropin subunit and GnRH 
receptor genes in rat pituitary in vitro and in vivo to clarify their expression profiles in the absence 
and continuous presence of GnRH. Culturing of pituitary cells in GnRH-free conditions downregulated 
Fshb, Cga, and Gnrhr expression, whereas continuous treatment with GnRH agonists upregulated 
Cga expression progressively and Gnrhr and Fshb expression transiently, accompanied by a prolonged 
blockade of Fshb but not Gnrhr expression. In contrast, Lhb expression was relatively insensitive to loss 
of endogenous GnRH and continuous treatment with GnRH, probably reflecting the status of Egr1 and 
Nr5a1 expression. Similar patterns of responses were observed in vivo after administration of a GnRH 
agonist. However, continuous treatment with GnRH stimulated LH secretion in vitro and in vivo, leading 
to decrease in LH cell content despite high basal Lhb expression. These data suggest that blockade of 
Fshb expression and depletion of the LH secretory pool are two major factors accounting for weakening 
of the gonadotroph secretory function during continuous GnRH treatment.
Mammalian reproduction depends on proper synthesis and release of two gonadotropins, luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH), by specialized endocrine cells of the anterior pituitary named 
gonadotrophs1. These hormones are dimeric glycoproteins composed of a common glycoprotein hormone, α 
polypeptide (Cga) and unique β subunits (Lhb and Fshb) that confer biological specificity2. The secretion of 
gonadotropins is tightly regulated by hypothalamic and intrapituitary factors. Among them, the most important 
is gonadotropin-releasing hormone (GnRH), which is released in a pulsatile manner by a small set of neurons 
within the preoptic area and mediobasal hypothalamus3. Upon reaching the anterior pituitary, GnRH binds to its 
receptor expressed in gonadotrophs and signals through a Gq/11-dependent cascade of intracellular pathways that 
culminates in periodic gonadotropin secretion4.
The pulsatile pattern of GnRH release is critical for proper gonadotropin synthesis and release. This was ini-
tially established in rhesus monkeys with hypothalamic lesions, which abolish endogenous GnRH secretion, 
where blood levels of LH and FSH were undetectable. Reintroduction of pulsatile GnRH administration rescued 
gonadotropin secretion, and subsequent continuous GnRH infusion lead to marked decrease in blood LH and 
FSH levels5. Subsequent experiments by the same group also revealed that LH levels were maximally stimu-
lated at a higher GnRH pulse frequency than FSH6. The requirement of pulsatile GnRH release for the proper 
reproductive function was subsequently confirmed in other mammalian species3. Several physiological responses 
and pathological conditions that cause reproductive failure in humans are also associated with dysregulation of 
pulsatile GnRH release, including functional hypothalamic amenorrhea, hyperprolactinemia, polycystic ovary 
syndrome, and hypogonadotropic hypogonadism7–10. Continuous GnRH receptor agonist treatments are also 
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clinically relevant, for example, for prevention of ovarian hyperstimulation syndrome during assisted reproduc-
tion11,12, for ovarian protection during chemotherapy13, and for treatments of precocious puberty14 and polycystic 
ovary syndrome15.
In general, the gonadotroph subunit genes, Cga, Fshb, and Lhb, exhibit basal and regulated expression, and it 
has been shown that they are stimulated by pulsatile GnRH application1. For example, in vivo pulsatile application 
of GnRH in male rats16, and in vitro pulsatile delivery of GnRH to cultured pituitary cells from male rats17 and 
pituitary fragments from female rats18 increased the transcription of gonadotropin subunit genes. In parallel to 
serum gonadotropin levels, Fshb was found to be preferentially transcribed at lower GnRH pulse frequencies, 
whereas Lhb was suggested to be preferentially transcribed at higher pulse frequencies administrated to male 
rats16,19 and to cultured pituitary cells from male rats17. Thus, the transcriptional regulation of gonadotropin sub-
unit genes by pulsatile GnRH could be a critical point that determines gonadotropin biosynthesis and secretion, 
suggesting the hypothesis that continuous GnRH treatment may cause downregulation of gonadotropin subunit 
gene expression, leading to downregulation of gonadotropin release.
However, the mechanism of downregulation of gonadotropin release by continuous GnRH treatment has not 
been clarified. Shupnik’s group observed stimulation of Fshb and Lhb transcription in static cultures of pituitary 
fragments from female rats during the first 6 h continuous application of GnRH, but they did not detect inhibition 
of basal expression of these genes18. The same group also reported lack of changes in Cga, Lhb, and Fshb transcrip-
tion compared to controls after continuous in vivo application of GnRH for 4 h in male rats16. In perifused rat 
pituitary cells, Fshb expression was stimulated by pulsatile delivery of GnRH for 12 h, but inhibited by continuous 
GnRH application, whereas Lhb mRNA levels were unresponsive to either mode of GnRH application20. The 
intrapituitary Fshb expression and circulating FSH levels are often highly correlated, and FSH was suggested to be 
secreted by constitutive exocytosis21 (and references within). In contrast, LH is secreted by regulated exocytosis22, 
i.e. GnRH receptor controls Lhb expression, LH release, or both.
Here, we evaluated the time course of gonadotropin subunit gene expression in static cultures of rat anterior 
pituitary during continuous GnRH treatment. We also studied the expression of transcription factor genes Egr1, 
Nr5a1, and Pitx1, which are critically important for control of expression of Lhb23–25. In addition, we character-
ized the acute and long-term effects of cell dispersion and primary culture in the absence of GnRH for these genes 
and commonly used reference genes before examining the effect of continuous GnRH treatment. Furthermore, 
we studied the relationship between Lhb expression, LH cell content, and LH release in vitro during continuous 
GnRH treatment. Finally, we evaluated effects of in vivo injection of a GnRH receptor agonist and antagonist on 
expression of gonadotropin subunit genes and LH serum and pituitary content. The expression of Gnrhr and 
Dmp1, which we characterized recently26,27, were used as internal controls in both in vitro and in vivo experi-
ments. Our results indicate that continuous GnRH application progressively stimulates Cga expression, blocks 
Fshb expression after a transient stimulation, and causes a profound effect on LH secretion without major effects 
on Lhb expression.
Methods
Animals and experimental procedures. In vitro experiments were performed with ante-
rior pituitary cells derived from 8-12-week-old Sprague Dawley rats obtained from Taconic Farms 
(Germantown, NY). Animals were euthanized via asphyxiation with CO2. After decapitation ante-
rior pituitary glands were removed and cells were mechanically dispersed after trypsin and EDTA 
treatments as previously described28. If not otherwise specified, experiments were performed with 
cells from females. Cells were seeded on poly-D-lysine coated 24-well plates and initially cul-
tured in medium 199 containing Earle’s salts, sodium bicarbonate, penicillin (100 units per ml), 
streptomycin (100 µg per ml) and 10% heat-inactivated horse serum (HS) (Life Technologies, Grand Island, 
NY). After overnight incubation, cells were bathed in medium 199 Earle’s salt solution containing 0.1% BSA 
in the presence of GnRH or D-Ala6-GnRH (D-Ala6) (Sigma, St Louis, MO). At the end of the experiments, 
incubation medium was collected, centrifuged at 3000 rpm to remove cell debris, and the supernatant was col-
lected and stored at −80 °C for determining LH concentration. Attached cells were scraped for RNA extraction 
or LH measurement. For in vivo experiments, 4-week old animals were injected once intraperitoneally with 
a GnRH receptor agonist, buserelin acetate (5 µg/0.4 ml/per animal) from Sigma (St. Louis, MO), a GnRH 
receptor antagonist, cetrorelix acetate (100 µg/0.4 ml/per animal) from Tocris (Minneapolis, MN), or vehicle 
(0.4 ml/per animal). Euthanasia was performed 0.5, 1, 1.5, 2, 3, 6, or 9 hours after intraperitoneal injections. 
After decapitation, blood was collected, and serum was separated and stored at −80 °C for LH concentration 
measurement. Whole anterior pituitaries were individually collected in RNA stabilization solution (Thermo 
Fisher Scientific, Waltham, MA) for RNA extraction or individually frozen without solution for measurement 
of LH tissue content (as described below). All experimental procedures were in accordance with the National 
Institutes of Health Policy Manual 3040-2: Animal Care and Use in the Intramural Program and were approved 
by the National Institute of Child Health and Human Development, Animal Care and Use Committee (Animal 
Protocol 16-041).
LH measurements. Concentration of LH in samples was determined using an LH Rodent Elisa Kit 
(Endocrine Technologies, Newark, CA), according to the manufacturer instructions. Samples (blood serum, 
incubation medium, pituitary tissue content and cell content) were diluted appropriately if needed. For LH tissue 
content measurements, pituitaries were homogenized in 20 mM sodium carbonate. The homogenate was centri-
fuged (3000 rpm) and supernatant was transferred to a new vial. Protein concentration was then measured by the 
PierceTM BCA assay (Thermo Fisher Scientific, Waltham, MA) and samples were equalized to contain the same 
total protein concentration prior to Elisa LH measurement.
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qRT-PCR analysis. Total RNA was extracted from individual anterior pituitary glands and primary cultures 
of anterior pituitary cells using an RNeasy Plus Mini Kit (Qiagen, Valencia, CA). RNA was reverse transcribed 
with a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Sciences, IN). An analysis of relative gene 
expression was performed using qRT-PCR and the comparative Ct method. For this, the LightCycler TaqMan 
Master Mix and the Lightcycler 2.0 Real-time PCR system (Roche Applied Science, Indianapolis, IN), or Power 
SYBR Green Master Mix and Quant Studio 3 system (Thermo Fisher Scientific, Waltham, MA) were used. Applied 
Biosystems predesigned TaqMan Gene Expression Assays were used: Cga: Rn01440184_m1, Lhb: Rn00563443_
g1, Fshb: Rn01484594_m1, Gnrhr: Rn00578981_m1, Dmp1: Rn01450122_m1, and Gapdh: Rn01462662_g1, 
Rpl19: Rn00821265_g1, Rps18: Rn01428913_gH, Egr1: Rn00561138_m1, Nr5a1: Rn00584298_m1, and Pitx1: Rn 
00586187_m1. The primer sequences (Integrated DNA Technologies, Skokie, IL) used in SYBR Green quantita-
tive real-time PCR are listed in Table S1.
To compare the relative expression levels of the transcripts, the levels were normalized against a reference 
gene, i.e. an internal reaction control that had sequences different than the target29. Several reference genes have 
been suggested for qRT-PCR analysis in anterior pituitary based on previous work with normal and pathological 
pituitary tissues and dispersed pituitary cells from different laboratories30–34. Figs. S1 and S2 show the expression 
patterns of these genes obtained from our single-cell RNA sequencing analysis of freshly dispersed male and 
female rat anterior pituitary cells35. Out of 19 genes studied, only eight genes were expressed in over 90% of ante-
rior pituitary cells: Rpl19, Rpl32, Rps18, Gapdh, Rpl4, Rplp0, B2m, and Actb. Among them, only five genes exhib-
ited comparable expression levels in all subpopulations of anterior pituitary cells: Rpl19, Rpl32, Rps18, Gapdh, 
and Rpl4. For further testing, we selected Rpl19, Rps18, and Gapdh because their Ct values, estimated in pituitary 
tissue, were comparable to the Lhb Ct values: Rpl19 = 21.46 ± 0.07; Rps18 = 22.37 ± 0.06; Gapdh = 23.85 ± 0.07; 
and Lhb = 22.15 ± 0.11.
To further study the validity of these candidate genes for qRT-PCR analysis of in vitro experiments, we exam-
ined the time-courses of their expression patterns after cell dispersion. We observed a decay in Ct values for all 
three candidate genes during the first 17 h of incubation, independent of the serum used for culturing (HS, BSA, 
or fetal bovine serum), suggesting that expression of these housekeeping genes increased after cell dispersion. 
To illustrate those changes, we used the Ct value at the beginning of experiments (zero time point, Ct(0)) as the 
reference value, computing the expression at later time points relative to time zero as: 2−(Ct(t)–Ct(0)), measured in 
relative units (RU) (Fig. S3A). After 17 h of incubation, the expression of candidate reference genes stabilized until 
the end of the experiments, i.e. until 96 h after cell dispersion (Fig. S3B). We also tested whether GnRH affects 
the expression of these candidate reference genes using female pituitary cells cultured overnight. The following 
morning, cells were washed and incubated in BSA-containing medium 199 supplemented with 10 nM GnRH for 
up to 8 h. Under these conditions the Ct values for Gapdh, Rpl19, and Rps18 did not change during incubation; 
Fig. S3C shows combined mean values from these experiments. 10 nM GnRH also had no effect on Gapdh expres-
sion during shorter and longer treatments (Fig. S3D).
Based on these findings, in further studies we used expression relative to time zero as described above to evaluate 
gene expression during the first 20 h of incubation after cell dispersion and termed such values as relative units (RU). 
For experiments done after 20 h of GnRH-free preincubation, such as those performed after overnight incubation, 
we used Gapdh and/or Rpl19 as reference genes for experiments and calculated expression relative to the reference 
gene as: 2^−(Ct(target gene) −Ct(reference gene)) × 100. To normalize values from several independent experi-
ments, we also presented such data as fold change relative to time zero, with initial values shown as one.
immunocytochemistry. For immunocytochemical analysis, 50,000/well freshly dispersed anterior pitu-
itary cells were plated on poly-D-lysine coated 8-well multitest slides (MP Biomedicals, Aurora, OH) and cul-
tured overnight. The following morning, cells were treated with 10 nM GnRH for 2, 4, 6 and 8 h. Cells were 
then washed twice with PBS and fixed with cold 4% formaldehyde solution (Thermo Scientific, Rockford, IL, 
USA) for 10 min at room temperature. After washing cells three times in PBS, cultures were bathed in medium 
with 1:200 rabbit anti-Egr1 15F7 (Cell Signaling Technology, Danvers, MA) or 1:100 mouse anti-Nr5a1 N1665 
(ThermoFisher Scientific, Waltham, MA) antibodies overnight at 4 °C, then incubated with appropriate second-
ary antibody (Alexa Fluor 488 donkey anti-mouse or Alexa Fluor 488 goat anti-rabbit; Invitrogen, Carlsbad, 
CA; 1:1000) for 30 min at room temperature. For double immunostaining, pituitary cells were incubated with 
guinea pig anti-Lhb (1:250) (obtained from Dr. A. F. Parlow, National Institute of Diabetes and Digestive and 
Kidney Diseases, National Hormone and Peptide Program, Torrance, CA) overnight at 4 °C, followed by subse-
quent incubation with a suitable secondary antibody (Alexa Fluor 568 goat anti-guinea pig antibody; Invitrogen, 
Carlsbad, CA; 1:1000 dilution) for 30 min at room temperature. All antibodies were diluted in staining PBS solu-
tion containing 0.2% saponin and 0.5% BSA. Every step of the immunostaining protocol was followed by wash-
ing cells three times with PBS. Cells were mounted with Fluoromount-G, with 4′,6-diamidino-2-phenylindole, 
a fluorescent DNA stain (Invitrogen, Carlsbad, CA). To test the specificity of the reaction, control cells were 
treated in the same way with the exclusion of primary antibodies (data not shown). All images were acquired on 
an inverted confocal laser-scanning microscope (LSM 780; Carl Zeiss GmbH, Jena, Germany), using a 63x oil 
objective. Micrographs were sized, and their brightness and contrast levels adjusted in Fiji. Cells were counted on 
5 tile-scan images (3 × 3).
Statistics. The numerical values are reported as the mean ± SEM from a representative set of at least 
three similar experiments, or normalized values from three to nine independent experiments per time point. 
KaleidaGraph (Synergy Software, Reading, Pennsylvania) was used for all calculation and graph presentation. 
Significant differences between means were determined by a single factor ANOVA or an ANOVA followed by the 
post hoc Student-Newman-Keuls test.
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Results
Basal gonadotropin subunit and GnRH receptor gene expression patterns in vitro. Freshly dis-
persed rat anterior pituitary cells were plated and cultured in medium without GnRH for four days. Because of 
transient changes in Ct values for Gapdh and other candidate reference genes during the first 20 h after cell disper-
sion, we measured expression relative to expression at time zero (RU), as described in Methods: qRT-PCR analysis. 
Figure 1A shows bidirectional changes in Lhb expression after cell dispersion; an initial minor stimulatory effect 
followed by a minor sustained inhibition. In contrast, there was an initial deep inhibition in Fshb expression 
followed by a partial recovery of expression (B), and a progressive inhibition of Cga (C) and Gnrhr expression 
(D). These results show that expression of Lhb was relatively insensitive to loss of endogenous GnRH, in contrast 
to Fshb, Cga, and Gnrhr expression. A partial recovery of Fshb expression during prolonged culturing without 
changes of bath medium could indicate an autocrine/paracrine stimulatory effect.
Gene-specific expression pattern during continuous GnRH receptor agonists application. In 
further experiments, anterior pituitary cells were cultured for 20 h after dispersion in the absence of GnRH, 
washed, and treated with 10 nM GnRH for 1, 2, 3, 4, 6, 8, 12, 18, and 24 h (Fig. 2A). Our control genes for this 
experiment, Gnrhr and Dmp1, responded as previously reported26,27; their expression was transiently stimulated, 
reaching a peak within 6 h of stimulation and followed by a gradual decay toward the basal level of gene expres-
sion (Fig. 2A). GnRH also stimulated Fshb expression transiently but peaking within 2–3 h of stimulation and 
followed by a rapid decay in gene expression below basal expression. After 6 h of incubation in the presence of 
GnRH, Fshb expression was abolished for the rest of the experiment. GnRH also stimulated Cga expression, but 
with a distinct temporal profile of expression; no changes in expression were observed during the first 8 h of cul-
turing, followed by a slow increase that reached a peak in response after 18 h of stimulation. Finally, we did not 
observe consistent stimulatory effects of GnRH on Lhb expression during continuous application; instead observ-
ing only a small and transient inhibition of basal expression during the first 12 h of incubation. Similar patterns of 
responses were also observed in cultured pituitary cells from postpubertal male rats (data not shown). These data 
indicate the gonadotropin subunit gene-specific patterns of responses to continuous in vitro GnRH application.
The progressive decay in Fshb, Gnrhr, and Dmp1 expression following the peak in response could reflect the 
rate of downregulation of stimulus-expression coupling in the presence of GnRH and/or the rate of GnRH deg-
radation. To rule out the latter, in further experiments we substituted native GnRH with its degradation-resistant 
analog D-Ala6, which was applied once or twice during a 23 h period in static cultures of female pituitary cells, as 
shown on the top panel of Fig. 2B. If applied twice, the culture medium was changed between applications to pro-
vide a washout period of variable duration. The profiles of gene expression during the first 12 h of application of 
D-Ala6 were highly comparable to those seen in GnRH application, with bidirectional effects on Fshb expression, 
stimulatory effect on Cga expression, and a small downregulation of Lhb. The washout of D-Ala6 did not affect 
Fshb expression during 15 h of incubation, as indicated by the lack of return of expression to the pre-application 
basal level. Also, the subsequent application of agonist at different time points was unable to elevate expression of 
this gene. Lhb expression recovered with and without secondary application of D-Ala6. The ongoing rise in Cga 
expression observed after removal of D-Ala6 was amplified 34 ± 14% by secondary agonist application. Finally, 
there was significant recovery of Gnrhr expression during the secondary D-Ala6 application, with the amplitude 
of responses increasing with extension of washout duration. For example, at the end of the experiments, the 
response of Gnrhr was 32 ± 4.5% of that observed during the first D-Ala6 application. These experiments estab-
lished that continuous GnRH in vitro downregulates Fshb expression, but not that of Cga, Lhb, and Gnrhr, below 
basal levels.
The lack of pronounced stimulation of Lhb expression during continuous 10 nM GnRH/D-Ala6 application, which 
is a pharmacological dose, prompted us to examine the full concentration dependence on GnRH of gene expression. To 
do this, static culture of pituitary cells were treated with 0.05, 0.1, 1, and 10 nM GnRH for 2, 4 and 6 h. The results of this 
concentration and time-course study, summarized in Fig. 3, confirmed the lack of a stimulatory effect and the presence 
of a minor inhibitory effect of GnRH on Lhb expression, with little effect of GnRH dose (Fig. 3A). In further parallel-
ism with previous experiments, we observed a bidirectional effect of GnRH on Fshb expression, an early stimulatory 
and a sustained inhibitory effect (Fig. 3B). The time-course of GnRH-stimulated Fshb expression was comparable at 
Figure 1. The expression patterns of gonadotropin subunit (A–C) and GnRH receptor (D) genes in rat anterior 
pituitary cells cultured in the absence of GnRH. Zero time points indicate the beginning of culturing after cell 
dispersion. Expression was measured relative to time zero in relative units (RU), as described in Methods: qRT-
PCR analysis. In all panels, asterisks indicate significant difference vs. zero time point controls.
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Figure 2. Time-course of GnRH receptor agonists on gonadotropin subunit genes, Gnrhr, and Dmp1 expression in 
cultured pituitary cells. (A) Effects of continuous GnRH application on gene expression. Note the transient nature 
of Fshb, Gnrhr, and Dmp1 expression, a slow and continuous upregulation in Cga expression, and a transient and 
minor inhibition of Lhb expression during GnRH treatment. Data shown are mean ± SEM values, normalized 
to the zero time point controls, from three to nine independent experiments per time point, each performed 
in quadruplicate. Asterisks indicate significant differences vs. zero time point. (B) A gene-specific patterns of 
expression in response to application of D-Ala6. Top panel indicates duration of first (blue) and second (red) 10 nM 
D-Ala6 application and washout periods (green). The data shown are mean ± SEM values from a representative 
experiment; when not visible, SEM values were within circles. Asterisks indicate a significant difference between 
pairs. In both panels, horizontal gray lines indicate basal gene expression and vertical dotted lines indicate times 
needed to reach the peak in expression. If not otherwise specified, in this and following figures experiments were 
performed with cells from postpubertal female rats. Immediately after dispersion, cells (1.5 million per well) 
were seeded in 24-well plates and cultured overnight in horse serum-containing GnRH-free medium. After 20 h 
incubation, medium was replaced with fresh 0.1% BSA-containing medium with GnRH or D-Ala6.
6Scientific RepoRtS |         (2019) 9:20098  | https://doi.org/10.1038/s41598-019-56480-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
all concentrations, with no effect of GnRH dose on the peak amplitude of responses, indicating maximal stimulatory 
action at picomolar GnRH concentrations. Conversely, downregulation of expression in the inhibitory phase was more 
pronounced with increasing GnRH concentration. The time course of GnRH-stimulated Gnrhr expression was also 
comparable at all GnRH concentrations, but the concentration dependence of this gene expression occurred later than 
the stimulatory component of the Fshb expression profile (Fig. 3C).
In vitro expression of pituitary transcriptional factors controlling Lhb expression. To better 
understand the expression profile of Lhb expression, we examined the responses of Pitx1, Egr1, and Nr5a1 to dis-
persion, culturing, and GnRH application. As stated in the Introduction, these transcription factors contribute to 
stimulation of Lhb expression. Dispersion/culturing of pituitary cells had dramatic effects on expression of these 
genes. There was a rapid, progressive, and deep decrease in Egr1 expression, whereas Pitx1 and Nr5a1 expression 
was facilitated in the same experimental conditions (Fig. 4A). In contrast, continuous GnRH application had a 
rapid and profound inhibitory effect on Nr5a1 expression, did not alter Pitx1 expression, and induced a transient 
increase followed by a recovery to near baseline of Egr1 expression, followed by a sustained plateau response 
(Fig. 4B). The opposite effects of culturing of cells without and with GnRH on Egr1 and Nr5a1 expression clearly 
indicates that this agonist plays an important role in their expression, stimulatory for Egr1 and inhibitory for 
Nr5a1, whereas the expression of Pitx1 was insensitive to GnRH and so appears to be controlled by other hypo-
thalamic and/or intrapituitary factor(s).
In further studies, the expression of Egr1 and Nr5a1 proteins was evaluated in anterior pituitary cells cultured 
overnight in horse serum-containing medium, washed in the morning and treated with BSA-containing medium 
with or without 10 nM GnRH. Following treatment, cells were double-stained with Egr1 or Nr5a1 and Lhb anti-
bodies as described in Methods: Immunocytochemistry. Prior to GnRH treatment, Egr1 immunoreactivity was 
detected only in 2% of Lhb-positive cells. Following 2 h GnRH treatment, there was a rapid rise in expression of 
Egr1 in Lhb-positive cells (37%). The number of Egr1-positive cells decreased with further duration of treatment, 
but stayed above basal expression (23, 12 and 9% following 4, 6 and 8 h treatment, respectively; Fig. 5A, left). 
In contrast, about 65% of Lhb-positive cells also expressed Nr5a1 in untreated cultures and there was a signifi-
cant decay in the fraction of Nr5a1 positive gonadotrophs after 6 h (45%) and 8 h (7%) of treatment with GnRH 
(Fig. 5A, right). Representative images for immune staining of Egr1- and Nr5a1-positive gonadotrophs are shown 
in Fig. 5B,C, respectively. The lack of effect of continuous GnRH application on stimulation of Lhb expression 
may be explained by the opposing responses in Egr1 and Nr5a1 expression after cell dispersion and during GnRH 
treatment. Also, the minor downregulatory effect of GnRH on basal Lhb expression indicates that the majority of 
basal Lhb expression is not GnRH controlled, in contrast to Fshb expression.
In vivo effects of buserelin and cetrorelix acetate on gonadotroph gene expression. Prepubertal 
female and male rats were injected with 5 µg of buserelin acetate, a GnRH receptor agonist, 100 µg of cetrorelix 
acetate, a GnRH receptor antagonist, or with vehicle (saline solution) intraperitoneally (Fig. 6). Animals were 
euthanized 0.5, 1, 1.5, and 2 h after injection (panel A), or 3, 6, and 9 h after injection (panels B-D), blood was 
Figure 3. Concentration- and time-dependent effects of GnRH on Lhb (A) Fshb (B) and Gnrhr (C) expression 
in cultured pituitary cells. GnRH was applied in 0.05–10 nM concentrations. Asterisks indicate significant 
differences vs. zero time point control (dotted lines).
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collected for serum LH measurements and pituitary glands were removed for qRT-PCR analysis or LH tissue 
content measurements. We observed significant increases in Lhb expression only at one time point, 30 min after 
injection of buserelin acetate. Notice the lack of buserelin acetate effect on Lhb expression independent of the 
gene used for normalization of data, Gapdh (Fig. 6B) or Rpl19 (Fig. 6C). However, buserelin acetate injection 
resulted in significant and transient increases in Fshb, Gnrhr, and Dmp1 expression and a progressive increase in 
Cga expression. The timing for Cga, Gnrhr, and Dmp1 expression in vivo was comparable to in vitro expression, 
whereas Fshb expression reached peak response already 30 min after the treatment, followed by decay in response 
and beginning of recovery of response after 9 h treatment (Fig. 7). Parallelism in the stimulatory actions of GnRH 
receptor agonists on gonadotropin subunit genes and Gnrhr expression in vitro and in vivo further supports the 
gene-specific expression pattern during continuous receptor activation.
independence of Lhb expression with respect to experimental conditions. It has been suggested 
that exposure of female pituitary cells to androgens is needed for establishing GnRH stimulus – transcriptional 
coupling36. To examine in vitro influence of androgens on Lhb expression, dispersed female pituitary cells were 
cultured overnight, washed and cultured for additional 24 h in the presence of 250 pg/ml dihydrotestosterone or 
500 pg/ml testosterone, as previously described37. Cell were then washed and stimulated with 10 nM GnRH in the 
presence of androgens for 1–6 h. Figure S4 summarizes these investigations. Consistent with experiments without 
Figure 4. The expression patterns of transcriptional factor genes controlling Lhb in anterior pituitary cells 
cultured in the absence and presence of GnRH. Changes in Pitx1, Egr1, and Nr5a1 expression in cells cultured 
for 96 h without GnRH (A) and in the presence of 10 nM GnRH, applied after 20 h culture in GnRH-free 
medium (B). Data points in A are mean ± SEM values from a representative experiment shown as relative 
units, and in B are normalized mean ± SEM values from four to nine experiments per time point, each done in 
quadruplicates. In all panels, asterisks indicate significant difference vs. zero time point controls.
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androgens (Fig. 2), GnRH also had a minor inhibitory effect on Lhb expression, but stimulated Gnrhr and Fshb 
expression during the first 6 h of exposure. The expression profiles for Gnrhr and Fshb were somewhat different in 
the presence of dihydrotestosterone and testosterone. Specifically, Gnrhr response was sigmoidal in the presence 
Figure 5. Immunofluorescence analysis of Egr1 and Nr5a1 expression in gonadotrophs. (A) Time course 
effect of GnRH treatment on Egr1 and Nr5a1 expression in Lhb-positive cells. (B,C) Representative images 
for immunocytostaining of Egr1- and Nr5a1-positive gonadotrophs. (B) Egr1 (green, left), Lhb (red, center), 
and their overlay (right) in untreated (top) and GnRH (10 nM/2 h) treated (bottom) pituitary cells. (C) Nr5a1 
(green, left), Lhb (red, center), and their overlay (right) in untreated and GnRH (10 nM/8 h) treated (bottom) 
pituitary cells. Cell nuclei are stained with DAPI (blue). Arrows indicate Lhb-positive gonadotrophs that express 
either Egr1 or Nr5a1. Scale bars (applies to all images), 10 µm.
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of dihydrotestosterone and linear in the presence of testosterone, and the duration of the upregulation phase of 
Fshb response was extended in the presence of testosterone (Fig. S4).
We also tested the validity of TaqMan probes and assay used for analysis. First, we used different TaqMan 
probes for Lhb and observed no difference in the expression pattern (data not shown). Second, we used static 
cultures of pituitary cells for 10 nM GnRH treatment (0 to 8 h) and SYBR-Green based assays with three different 
pairs of primers for evaluation of Lhb mRNA levels (Fig. S5A; Table S1). Consistent with the TaqMan assay, no 
stimulatory effect of GnRH on Lhb expression was observed by SYBR-Green assay. Finally, both TaqMan and 
SYBR-Green assays were used to evaluate in vivo Lhb expression after buserelin acetate and cetrorelix acetate 
injections; Fig. S5B summarizes results with TaqMan assay (left) and SYBR-Green assay (middle) and a significant 
correlation between values was obtained by the two assays (right), indicating the validity of both assays.
Characterization of the LH secretory actions of GnRH receptor agonists in vitro and in vivo. For 
secretory studies, 0.25 × 106 cells per well were cultured in 24-well plates overnight, washed in the morning and 
stimulated with 10 nM GnRH for 1–5 h. At the end of incubation, medium was collected, and LH was measured 
in incubation medium and cellular extracts. Figure 8 illustrates the time-courses of GnRH-induced LH release 
(A) and depletion of intracellular LH content (B); the time-dependent increase in LH release was accompanied 
by a progressive decrease in hormonal cell content. We also examined effects of cycloheximide, an inhibitor of 
eukaryotic protein synthesis, on 10 nM GnRH-induced LH release during 4 h incubation. This compound caused 
a profound reduction of GnRH-stimulated LH secretion (C), indicating that high basal Lhb and Cga transcription 
leads to de novo LH synthesis.
In vivo injection of buserelin acetate also triggered LH secretion, as documented by measurements of serum 
LH concentration. There was a rapid increase in serum LH concentration, reaching a peak in secretion 90 min 
after injection, followed by a gradual decay (Fig. 8D). The spike phase temporally coincided with a rapid fall in 
pituitary LH tissue content (Fig. 8E). Nine hours after buserelin acetate treatment, pituitary LH tissue content was 
about 6% of that observed in controls. Taken together, these experiments indicate that during continuous treat-
ment with high concentrations of GnRH receptor agonists there was no blockade of stimulus-secretion coupling 
and that basal Lhb expression and de novo LH synthesis are not sufficient to protect cells from depletion of the 
secretory pool.
Discussion
Here we examined the dependence of gonadotropin subunit and GnRH receptor gene expression patterns on 
GnRH in vitro and in vivo. After cell dispersion and culturing in GnRH-free medium, we observed a rapid decay 
in Fshb, Cga, and Gnrhr expression, but only a small decay in Lhb expression. We also showed significant changes 
in expression of reference genes commonly used for quantification of relative expression by qRT-PCR in the 
same conditions, but not in response to GnRH treatment, necessitating careful analysis in the first 20 h of pri-
mary culture. In further agreement with the role of GnRH receptors in Fshb, Cga, and Gnrhr expression, in vitro 
continuous treatments with both GnRH and its degradation-resistant analog D-Ala6 stimulated the expression 
Figure 6. Effects of in vivo injection of a GnRH receptor agonist and antagonist on Lhb expression. 
Experiments were performed with prepubertal female and male rats. (A–D) Effects of injection of buserelin 
acetate, a GnRH receptor agonist (5 µg/0.4 ml per animal), cetrorelix acetate, a GnRH receptor antagonist 
(100 µg/0.4 ml per animals,) or solvent (0.4 ml PBS) intraperitoneally. Animals were sacrificed 0.5, 1, 1.5 and 2 h 
after injection (A) or 3, 6 and 9 h after injection (B–D). Values were normalized vs. Gapdh (A,B,D) or Rpl19 (C).
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of these genes, but with gene-specific kinetics. Fshb expression was bidirectional, with a rapid but transient upreg-
ulation, followed by a sustained downregulation in expression below the basal value observed in untreated cell 
cultures. Gnrhr expression was also transient, but with a delay in peak expression and without downregulation 
of expression below basal levels. Cga expression was only upregulated with about 6–8 h-delay in beginning of 
rise in expression. In contrast, we did not consistently observe upregulation of Lhb expression, and we recorded 
only a minor and transient inhibition from basal Lhb expression levels during the continuous presence of GnRH 
Figure 7. Effects of in vivo injection of a GnRH receptor agonist and antagonist on Fshb, Cga, Gnrhr, and Dmp1 
expression. Experiments were performed with prepubertal female rats sacrificed 0.5, 1, 1.5 and 2 h after injection 
(A) or 3, 6 and 9 h after injection (B,C).
Figure 8. GnRH receptor agonist-stimulated LH secretion in vitro and in vivo. (A,B) Time-courses of GnRH-
induced LH release (A) and depletion of intracellular LH content (B). After overnight incubation, cells were 
stimulated with 10 nM GnRH for 1–5 h. At the end of incubation periods, medium (A) and cell lysates (B) were 
collected for LH measurements. (C) Concentration-dependent effect of cycloheximide, a eukaryote protein 
synthesis inhibitor, on 10 nM GnRH-induced LH release following 4 h incubation (normalized values). Asterisks 
indicate significant differences vs. untreated cells. (D,E) In vivo effects of buserelin acetate on serum (D) and 
intrapituitary (E) LH. Data shown are mean ± SEM, N = 5 per time point. Panels D and E shows combined data 
from short-term and long-term treatment with buserelin acetate and control females (compare Figs. 6 and 7).
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receptor agonists. In vivo injected buserelin acetate also transiently stimulated Fshb, Cga, and Gnrhr expression 
without obviously affecting Lhb expression. The expression of Dmp1, another gonadotroph-specific gene, was 
comparable to Gnrhr expression kinetics.
To our best knowledge, we present the first study of the effects of culturing cells in GnRH-free medium on 
the time course of expression of these genes, starting immediately after cell dispersion. We also believe this is the 
first detailed time-course analysis of the effects of continuous GnRH receptor agonist treatments on gonadotro-
pin subunit gene expression in the rat model. Others have observed up-regulation in Fshb expression 1 h after 
GnRH application in rat pituitary fragments18 and downregulation in expression of this gene in rat pituitary 
cells cultured for 8 and 24 h in the presence of GnRH20 and 24 h after continuous exposure to GnRH in cultured 
mouse pituitary cells38. In contrast to our results, Shupnik reported stimulation in Lhb expression in static culture 
of rat pituitary fragments, and rapid effects (within 30 min) on Cga expression18. However, Weiss et al. reported 
no stimulatory effect of continuous GnRH treatment of cultured rat pituitary cells on Lhb expression 4, 8, and 
24 h after continuous stimulation with GnRH20. The lack of effect of GnRH treatment on Lhb expression was also 
observed in pituitary cells from ovariectomized rats39. In contrast to gonadotropin subunit genes, previous exper-
iments have well clarified that expression of Gnrhr decays during prolonged culturing in the absence and presence 
of GnRH26,40,41. GnRH treatment also elevates Dmp1 expression in vitro with similar kinetics and concentration 
dependence27,42. The same conclusion was reached in this study, which gave us confidence about the reproducibil-
ity of in vitro experiments and the validity of the novel conclusions for expression of gonadotropin subunit gene 
expression during continuous in vitro application.
Our experiments lead to at least four major conclusions: 1. The lack of ability of continuous GnRH treat-
ment to modulate Lhb expression is consistent with the hypothesis that a pulsatile pattern of GnRH appli-
cation may be a pre-requisite for detecting the upregulation in Lhb expression, which has been previously 
reported16–18. 2. Continuous GnRH treatment not only transiently stimulates Fshb expression, but also 
downregulates basal Fshb expression. FSH is known to be predominantly secreted by constitutive exocytosis. 
Consequently, the intrapituitary Fshb and circulating FSH levels are often highly correlated; i.e. Fshb expres-
sion is a good indicator of the secretory profile21. Thus, it is reasonable to conclude that blockade of Fshb 
expression by continuous GnRH treatment accounts for downregulation of FSH release in such treatments. 
3. The difference in the peak response times for Fshb, Gnrhr/Dmp1, and Cga could provide a rationale for 
the observed differences in the GnRH pulse frequency in regulation of expression of these Fshb (low), Gnrhr 
(high), and Cga (high or continuous). This motivates further experiments to clarify the differences in the intra-
cellular messengers and/or transcriptional factors controlling their expression. 4. Such divergent patterns of 
expression of gonadotropin subunit and GnRH receptor genes strongly argue against desensitization of GnRH 
receptors during continuous treatment. This is consistent with previous findings that the type I mammalian 
GnRH receptor does not desensitize, in contrast to other G protein-coupled receptors43 and non-mammalian 
forms of this receptor44. Our results also indicate that receptor signaling pathways are functional during con-
tinuous stimulation, accounting for a prolonged upregulation and downregulation of Cga and Fshb expression, 
respectively, and continuous LH secretion.
To understand why no stimulatory action of GnRH on Lhb expression was observed during continuous recep-
tor activation, we studied the expression pattern of three transcription factors, Egr1, Nr5a1, and Pitx1, which 
have been suggested to be critical for controlling basal and/or GnRH receptor-regulated Lhb expression45. Egr1 
null female mice are infertile and lack expression of Lhb24. This gene is induced rapidly by GnRH in immortalized 
gonadotrophs46 and cultured rat pituitary cells27,47. The action of Egr1 protein on Lhb transcription depends on 
Nr5a1 and Pitx125,48, and such a pattern of regulation is largely conserved among mammals49. Consistent with 
this model, it has been suggested that GnRH stimulates Nr5a1 expression50. However, others reported inhibitory 
effects of GnRH on expression of this gene51. In our preparation, Egr1 and Pitx1 were expressed in all subpopu-
lations of pituitary cells, including gonadotrophs, whereas Nr5a1 was detected only in gonadotrophs35. Here we 
showed that Egr1 expression rapidly declined and that protein expression was observed only in 2% of cells after 
20 h incubation in GnRH-free medium. The loss of Egr1 proteins in cultured gonadotrophs was not accompa-
nied by dramatic changes in basal Lhb expression. The subsequent addition of GnRH only partially restored the 
expression of this gene and protein. Furthermore, Nr5a1 gene and protein expression was downregulated during 
continuous GnRH application. Thus, it is reasonable to speculate that basal Lhb expression is independent of the 
presence of Egr1 and that pulsatile GnRH application is required for the proper expression of Egr1/Nr5a1 and 
their coupling to Lhb expression.
The presence of high basal Lhb expression combined with the lack of sustained downregulation in Lhb expres-
sion during continuous GnRH application raised a question concerning the mechanism accounting for downreg-
ulation of LH secretion. It is well established that LH is predominantly secreted by regulated exocytosis22, and that 
GnRH is a very potent secretagogue1, which led us to examine the status of LH secretion under conditions used 
for studies on Lhb expression. We observed downregulation of LH secretion in vitro during sustained application 
of high concentrations of GnRH despite sustained Lhb expression. We also observed almost complete depletion 
of the LH secretory pool in gonadotrophs in vivo after injection of buserelin acetate despite elevated Lhb expres-
sion. These results indicate that downregulation of secretion occurs downstream of Lhb expression, probably at 
the level of de novo LH synthesis and/or maintenance of the secretory pool. It has already been suggested that 
translational control of gene expression could provide a rationale for some aspects of GnRH receptor signaling 
and secretion that could not be explained by changes at the level of transcription52. In that respect, it is illustrative 
that cycloheximide, an inhibitor of translational elongation, has a profound and time-dependent effects on LH 
release. These findings raise the possibility that pulsatile GnRH provides a mechanism for sustained LH release 
by allowing sufficient time for de novo LH synthesis to replenish the LH secretory pool. Further experiments are 
needed to clarify the status of LH secretory pool during sustained application of variable GnRH concentrations, 
and the kinetics of repletion of the secretory pool after removal of GnRH receptor agonists.
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